Analyst consensus rating

Royalty Pharma Analyst Rating: Buy

Direct answer

Royalty Pharma's consensus rating is Buy.

8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $75.25.
Forecast evidence checked November 21, 2026.

Get free Royalty Pharma email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$68.45
Average price target
$75.25
High price target
$80.00
Low price target
$67.00
Low target gap
-2.1%
Target upside
+9.9%
High target gap
+16.9%
Target range width
19%
Consensus rating
Buy
Analysts
8
Evidence date
November 21, 2026
Valid through
November 28, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Royalty Pharma?

Royalty Pharma has a verified Buy consensus. The same dataset has an average price target of $75.25.

How far are Royalty Pharma's low and high targets from the recorded price?

The low target implies -2.1%, while the high target implies +16.9%.

How many analysts are included in Royalty Pharma's consensus?

The verified consensus includes 8 analysts.

How is Royalty Pharma's target upside or downside calculated?

The average target of $75.25 is divided by the recorded price of $68.45, then one is subtracted to produce +9.9%. This does not guarantee a future return.

When was Royalty Pharma's analyst forecast verified?

The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.